Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-31
2006-01-31
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S587000
Reexamination Certificate
active
06992079
ABSTRACT:
The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
REFERENCES:
patent: 3546155 (1970-12-01), Morgan
patent: 4006023 (1977-02-01), McLaughlin et al.
patent: 4806685 (1989-02-01), Abraham et al.
patent: 5273992 (1993-12-01), Brugnara et al.
patent: 5358959 (1994-10-01), Halperin et al.
patent: 5430062 (1995-07-01), Cushman et al.
patent: 5512563 (1996-04-01), Albright et al.
patent: 6063921 (2000-05-01), Moussa et al.
patent: 6201120 (2001-03-01), Moussa et al.
patent: 6291449 (2001-09-01), Lencer et al.
patent: 6534497 (2003-03-01), Brugnara et al.
patent: 2001/0007030 (2001-07-01), Moussa et al.
patent: 0 323 740 (1989-07-01), None
patent: 0 583 665 (1994-02-01), None
patent: 0 636 608 (1995-02-01), None
patent: 05 58894 (1993-03-01), None
patent: WO 95/26720 (1995-10-01), None
patent: WO 96/08240 (1996-03-01), None
patent: WO 96/08242 (1996-03-01), None
patent: WO 96/36631 (1996-11-01), None
patent: WO 99/26928 (1999-06-01), None
Starnes, Jr., Chem. Abstract 69:43555. 1968.
Koelsch. Chem. Abstract 55:9360. 1961.
Gagnon, Beilstein Reg. No. 4924895. 1929.
Dakkouri et al., Chem. Abstract 125:305256, 1997.
Enokida et al., Chem. Abstract 125:39835, 1996.
Banli et al., Chem. Abstract 107:58774, 1987.
Manning et al., Chem. Abstract 94:102538, 1981.
Omenn, Cancer Prevention, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1008-1010, 1996.
Sasakura et al., Synthesis of 11-phenyl-5,6-dihydro-11H-dibenz(b,e)azepine derivatives, Heterocycles, vol. 15, No. 1, pp. 421-425, 1981.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1008, 1996.
Brugnara, C., et al., “Oral Administration of Clotrimazole and Blockade o Human Erytrocyte Ca++—Activated K+ Channel: the Imidazole Ring is not Required for Inhibitory Activity,”JPRT273:266-272 (1995).
Skehan, P., et al., “New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening,”J. Natl. Cancer Inst. 82:1107-1112 (1990).
Aldrich Catalog, 1994-1995: Compounds 13, 484-8; T8,380-1; 10.130-3; D21,320-9; 32,543-0; 35,890-8; T8.160-4; 25,657-9; T8.470-0; T8.417-7; T8,360-7; S36.533-5; S50,949-3; 37,411-3; 37,152-1; 30.151-5; 27,520-4; 34.182-7; 35,889-4; 584,240-0; S79.226-8; 27,519-0; S64,640; S81,477-6; 36,005-8; S70.627-2; S34,966-6; S87.739-5; 11,500-2; S83,881-0; S58.110-0; 21.560-0; S91,408-8; S60,147-0; S83,571-4; S82,654-5; S8,388-2; S94,371-1; S87,649-6; S83,719-9; S83,042-9; S823,162-4; S81,468-7; S82,290-6; S79,387.
Ando, W., et al., “A Novel Reduction of α-Aryl Alkanols by Diiododimethylsilane,”Tetrahedron Letters, 51:4941-4942 (1979).
Barton, D. H. R., et al., “Pentavalent Organobismuth Reagents. Part 3. Phenylation of Enols and of Enolate and Other Anions.”J. Chem. Soc. Perkin Trans., 1:2667-2675 (1985).
Barton, D. H. R., et al., “Pentavalent Organobismuth Reagents. Part 3. Phenylation of Enols and of Enolate and Other Anions.”General Org. Chem., 105:531, col. 2, Abstract No. 208158b (1986).
Bartroli, J., et al., “Synthesis and Antifungal Activity of a Series of Difluorotritylimidazoles,”Arzneim.-Forsch./Drug Res., 42[1](6):832-835 (1992).
Benjamin, L. J., et al., “A Collaborative, Double-Blind Randomized Study of Cetiedil Cirrate in Sickle Cell Crisis,”Blood, 67(5):1442-1447 (1986).
Benzaquen, L. R., et al., “Clotrimazole Inhibits Cell Proliferation in vitro and in vivo,”Nature Medicine, 1(6):534-540 (1995).
Bergman, J., et al., “Synthesis and Studies of Tris-Indolobenzenes and Related Compounds,”Tetrahedron, 36:1445-1450 (1980).
Bergman, J., et al., “Synthesis and Studies of Tris-Indolobenzenes and Related Compounds,”Chemical Abstracts, 94:368, col. 1, Abstract No. 3948s (1981).
Berkowitz, L. R., et al., “An Analysis of the Mechanism by Which Cetiedil Inhibits the Gardos Phenomenon,”American Journal of Hematology, 17:217-223 (1984).
Beutler, E., et al., “The Removal of Leukocytes and Platelets from Whole Blood,”J. Lab. Clin Med., 88(2):328-333 (1976).
Bontems, F., et al., “Analysis of Side-Chain Organization on a Refined Model of Charybdotoxin: Structural and Functional Implications,”Biochemistry, 31:7756-7764 (1992).
Brugnara, C., et al., “Ca2+-Activated K−Transport in Erythrocytes,”Journal of Biological Chemistry, 268(12):8760-8768 (1993).
Brugnara, C., et al., “Inhibition of Ca2−-Dependent K−Transport and Cell Dehydration in Sickle Erythrocytes by Clotrimazole and Other Imadazole Derivatives.”J. Clin. Invest., 92:520-526 (1993).
Brugnara, C., et al., “Inhibition of Gardos Channel and Red Cell Dehydration by Oral Administration of Clotrimazole in Sickle Cell Disease,”Blood, 220a:865 (1994).
Brugnara, C., et al., “Inhibition of Gardos Channel and Red Cell Dehydration by Oral Administration of Clotrimazole in Sickle Cell Disease,”The 20thAnnual Meeting of the National Sickle Cell Program, p. 138 (1995).
Brugnara, C., et al., “Erythrocyte Gardos Channel and Sickle Cell Disease: Pathophysiology and Clinical Significance,”Advanced Course and International Symposium on “Membrane Transporters and Channels” Program and Abstracts, Lecture 34 (1995).
Brugnara, C., et al., “Therapy with Oral Clotrimazole Induces Inhibition of the Gardos Channel and Reduction of Erythrocyte Dehydration in Patients with Sickle Cell Disease,”J. Clin. Invest., 97(5):1227-1234 (1996).
Burgess, M.A., et al., “Clotrimazole (Bay b 5097): In Vitro and Clinical Pharmacological Studies”Antimicrobial Agents and Chemotherapy, 2(6):423-426 (1972).
Byers, H.R., et al., “Organ-Specific Metastases in Immunodeficient Mice Injected with Human Melanoma Cells: a Quantative Pathological Analysis,”Melanoma Research, 3:247-253 (1993).
Carter, A. J., et al., “Morphologic Characteristics of Lesion Formation and Time Course of Smooth Muscle Cell Proliferation in a Porcine Proliferative Restenosis Model,”JACC, 24(5):1398-1405 (1994).
Charache, S., et al., “Failure of Desmopressin to Lower Serum Sodium or Prevent Crisis in Patients with Sickle Cell Anemia,”Blood, 58(5):892-896 (1981).
Charache, S., et al., “Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia,”The New England Journal of Medicine, 332(20):1317-1322 (1995).
Clark, M. R., et al., “Hydration of Sickle Cells Using the Sodium Ionophore Monensin,”J. Clin. Invest., 70: 1074-1080 (1982).
Conte, L., et al., “Percutaneous Absorption and Skin Distribution of [14C]Flutrimazole in Mini-pigs,”Arzneim.-Forsch./Drug Res., 42[1](6):847-853 (1992).
Conte, L., et al., “Pharmacokinetic Study of [14C]Flutrimazole after Oral and Intravenous Administration in Dogs,”Arzneim.-Forsch./Drug Res., 42[1](6):854-858 (1992).
Corbett, T. H., “Preclinical Anticancer Activity of Cryptophycin-8,”Journal of Experimental Therapuetics&Oncology, 1:95-108 (1996).
DeFranceschi, L., et al., “Treatment with Oral Clotrimazole Blocks Ca2+-Activated K−Transport and Reverses Erythrocyte Dehydration in Transgenic SAD Mice,”J. Clin. Invest., 93:1670-1676 (1994).
DeFranceschi, L., et al., “Reduction of K-Cl Cotransport-Mediated Erythrocyte Dehydration by Dietary Magnesium Supplements in Patients with Sickle Cell Disease.”Blood, 548a:2580 (1996).
Duchene, P., et al., “Pharmacokinetic Profile of [14C]Flutrimazole Following Single Topical Application in Normal and Scarified Skin of Healthy Volunteers,”Arzneim.-Forsch./Drug Res., 42[1](6):861-863 (1992).
Duhm, B., et al., “The Pharmacokinetics of Clotr
Bellott, Jr. Emile M.
Brugnara Carlo
Clifford John J.
Fluckiger Rudolf
Gao Ying-Duo
Children's Medical Center Corporation
Fish & Richardson P.C.
NuChem Pharmaceuticals Inc.
President & Fellows of Harvard College
Rao Deepak
LandOfFree
Substituted 11-phenyl-dibenzazepine compounds useful for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 11-phenyl-dibenzazepine compounds useful for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 11-phenyl-dibenzazepine compounds useful for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3544087